Patients who experience heart attacks often have immediate ischemia and cell death, which causes a decrease in cardiac function, contributing to higher mortality and morbidity.
One of the main shortcomings of the clinical use of Hematopoietic Stem Cells (HSCs) is the limited number of cells that can be safely harvested from a patient.
Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.